- Home
- SA vs NAMS Comparison
SA vs NAMS Comparison
Compare SA & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SA | NAMS |
|---|---|---|
| Founded | 1979 | 2019 |
| Country | Canada | Netherlands |
| Employees | N/A | 100 |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 4.1B |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | SA | NAMS |
|---|---|---|
| Price | $34.57 | $31.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $65.00 | $46.75 |
| AVG Volume (30 Days) | 832.9K | ★ 1.5M |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $17.96 |
| Revenue Next Year | N/A | $540.65 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.00 | $17.76 |
| 52 Week High | $40.06 | $42.21 |
Technical Indicators
Market Signals| Indicator | SA | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 60.49 | 41.88 |
| Support Level | $27.50 | $30.34 |
| Resistance Level | $40.06 | $37.27 |
| Average True Range (ATR) | 1.76 | 1.71 |
| MACD | 0.52 | -0.59 |
| Stochastic Oscillator | 89.44 | 15.19 |
Price Performance
Historical ComparisonAbout SA Seabridge Gold Inc. (Canada)
Seabridge Gold Inc is a development stage company involved in the exploration and development of gold properties situated in North America. The company's principal projects include the Kerr-Sulphurets-Mitchell property located in British Columbia, the Courageous Lake property located in the Northwest Territories, the Iksut Property located in northwestern British Columbia, and the 3 Aces Project in southeast Yukon. The company has various other mineral resource projects throughout North America.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.